Entities

Oern R. Stuge is published by Sectoral Asset Management as Industry Partner (published affiliation). Medical-device executive with Orsco Lifesciences and earlier Medtronic leadership experience. Existing canonical OernStuge also has Carthera chair history, which is preserved.

Panakès Partners is a Milan-based venture capital manager investing in early-stage life-science startups and innovative SMEs, primarily in Europe. It finances therapeutic medicines, medical devices, diagnostics and healthcare technologies and supports scientific teams with business development and clinical and industrial networks. Its portfolio spans neuromodulation for tinnitus and migraine, Alzheimer diagnostics, robotic microsurgery, oncology and cardiovascular treatments. Its BII Catalyst Fund I for Italy supports early-stage Italian therapeutics companies in partnership with the BioInnovation Institute, Lazio Innova and Novo Holdings.

Novac is an Italian advanced-materials and energy-storage company developing and manufacturing proprietary supercapacitors and customised systems that combine them with batteries. Its pouch-format and shapeable supercapacitors supply rapid power bursts and recover energy in electric and hybrid vehicles, aerospace systems, marine propulsion and industrial equipment. Founded in Modena in 2020 after a university project begun in 2018, the company operates its own research laboratory and is scaling pilot production of its technology.

MapLight Therapeutics clinical adviser and Banner Alzheimer’s Institute director. Researches dementia care, prevention and treatment trials, biomarkers and neuropsychiatric symptoms. Trained in medicine at Rochester and previously worked at NIMH and Rochester.

MapLight Therapeutics clinical adviser and director of the University of Rochester AD-CARE program. Researches memory disorders, Alzheimer’s disease clinical trials, biomarkers and behavioral symptoms. Holds a medical degree from the University of Iceland.

MapLight Therapeutics clinical adviser and biotechnology clinical development consultant. Former Alkermes medical and clinical leader and Northwestern pediatric endocrinologist. Studied biophysics at Pennsylvania and medicine at Mount Sinai.

MapLight Therapeutics clinical adviser and CognitionMetrics president. Neuropsychologist advising CNS clinical programs on cognition and psychometrics; previously worked at Cogstate and AstraZeneca. Holds a Yeshiva doctorate and a John Jay public administration degree.

MapLight Therapeutics clinical adviser and Hofstra/Northwell psychiatry professor studying schizophrenia treatment and recovery. Previously chaired psychiatry at Zucker Hillside Hospital and the Zucker School of Medicine. Earned a medical degree at NYU.

Clinical advisory board member of ProMIS Neurosciences and MapLight Therapeutics, and founder and chief executive of Pentara. Statistician specializing in Alzheimer’s disease and degenerative conditions, with a Boston University doctorate.

MapLight Therapeutics clinical adviser and Stony Brook psychiatry chair. Researches dopamine transmission and brain imaging in schizophrenia and addiction, including PET methods. Holds a medical degree from St. Joseph University in Beirut and trained at Tennessee, NIMH and Yale.

MapLight Therapeutics scientific adviser and Stanford neurosurgery and neuroscience professor. Studies neuronal circuits, oscillations and epilepsy mechanisms. Earned a doctorate at Eötvös University and previously led a laboratory and department at UC Irvine.

MapLight Therapeutics scientific adviser and Allen Institute for Brain Science executive vice president and director. Leads research on brain cell types and connectivity atlases. Holds a Brandeis molecular and cell biology doctorate and completed postdoctoral research at MIT.

MapLight Therapeutics scientific adviser and UCSF psychiatrist and geneticist studying neurodevelopmental disorders. His research uses genetic discoveries to investigate autism and related syndromes. Trained in medicine at Stanford and genetics at Yale; previously held a Yale faculty position.

MapLight Therapeutics director with finance and investment operating experience. Former founding partner and chief financial officer of Patient Square Capital; earlier held senior roles at KPMG, Forward Ventures and Lightspeed Venture Partners. Co-founded the now dormant Alzheimer’s startup Recuerdo Therapeutics.

Director at MapLight Therapeutics and Stellaromics and chief executive of a Silicon Valley single-family office. Has experience across investment management, public and private companies and nonprofit boards.

MapLight Therapeutics director and Forbion general partner focusing on clinical-stage biotechnology. Previously invested at Novo Holdings and Apposite Capital. Holds a UCL neuroscience doctorate, a Cambridge MBA and an Oxford undergraduate degree.

MapLight Therapeutics independent director. Previously spent more than two decades at Eli Lilly, including chief medical officer duties from 2008 to 2021, overseeing clinical development, medical affairs and regulatory work across several therapeutic areas.

MapLight Therapeutics director. Former Foundation Medicine chief executive and Genentech senior executive, with earlier CNS leadership experience at UCB. His MapLight biography also identifies him as board chair of SOPHiA GENETICS.

MapLight Therapeutics director and Alumis president, chief executive and board chair. Previously led Principia Biopharma through its acquisition by Sanofi and served as Talima Therapeutics chief executive and a Genentech commercial leader.

MapLight Therapeutics co-founder and scientific adviser. Stanford psychiatry professor and Wu Tsai Neurosciences Institute deputy director researching synaptic biology. Previously taught at UCSF. Holds Stanford medical and neuroscience doctoral degrees and an undergraduate degree from Harvard.

Stanford neuroscience professor and physician; scientific co-founder and adviser at Stellaromics and co-founder and scientific adviser at MapLight Therapeutics. Research developed optogenetics and STARmap-related spatial biology methods.

MapLight Therapeutics general counsel, also known formally as Kristopher L. Hanson. Previously led legal and compliance work at PhaseBio and Nalpropion and served in senior legal roles at Orexigen and other companies. Studied at Georgetown and UCLA School of Law.

MapLight Therapeutics chief discovery officer, developing neural-circuit discovery methods. Previously a UCSF physiology and neurology professor researching basal ganglia function, Parkinson’s disease and dyskinesia. Studied at Berkeley and Harvard and trained at Stanford.

MapLight Therapeutics interim chief financial officer and chief administrative and accounting officer. Previously led finance at OvaScience and worked in external reporting at GFI Software and audit at PwC. Holds undergraduate and graduate accounting degrees from Babson.

MapLight Therapeutics chief scientific officer, responsible for preclinical research. Former OvaScience scientific leader and Sanofi Genzyme vice president of in vitro biology; earlier worked at Millennium and Scriptgen. Holds a Harvard doctorate and a Wesleyan undergraduate degree.

MapLight Therapeutics chief medical officer and cognitive neurologist. Previously directed dementia and neurodegeneration clinical programs at Acadia Pharmaceuticals and conducted translational research at the University of Virginia. Holds a Baylor genetics doctorate and a Jefferson medical degree.

MapLight Therapeutics co-founder, chief executive and director; also serves on Stellaromics’ board. Physician and biotechnology executive who previously led Cardioxyl and OvaScience and invested at The Aurora Funds.

MapLight Therapeutics is a clinical-stage neuroscience biotechnology company developing medicines for central nervous system disorders. Its discovery approach combines neural-circuit mapping, optogenetics and molecular profiling to identify disease-related circuits and targets for drug development. Programs include the investigational muscarinic-receptor combination ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis and ML-004 for autism-related symptoms. Christopher Kroeger leads the company; scientific founders include Karl Deisseroth and Robert Malenka. Its public roster includes management, directors, scientific advisers and clinical advisers. MapLight began Nasdaq trading under MPLT on October 27, 2025. Financing includes a USD225 million Series C, a Series D with USD200 million actually raised against a larger announced commitment, an IPO with approximately USD288.36 million gross proceeds, a separate concurrent private placement of approximately USD8.10 million and a USD150 million PIPE announced in August 2026. Its programs remain investigational.

Eureka! Venture SGR is an independent Italian venture capital manager investing in scientific and proprietary deep technologies, technology transfer and digital technology. Its Eureka funds finance research spin-offs, startups and innovative SMEs through validation, industrialisation and international growth, including advanced materials, energy, health, robotics, physical AI and quantum technology. The manager also operates the BlackSheep marketing-technology investment strategy and an Entrepreneurship Through Acquisition strategy investing in search funds.

IAG publishes Luigi Capello as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: CEO di LVenture Group. Digital Deep Tech Imprenditore e Business Angel di successo, Luigi ha gestito importanti fondi di Private equity e nel 2007 ha cofondato IAG – Italian Angels for growth. Luigi è inoltre fondatore di Luiss Enlbas, acceleratore di startup digitali. Attualmente Luigi è CEO di LVenture Group, Fondo VC quotato in Borsa Italiana. Luigi è stato inoltre menzionato dalla community “Hot Topics” nella lista dei 100 leader più influenti di acceleratori di startup.

Head of the risk-management function published by Vertis. Junior Partner at Quantyx, responsible for venture-capital-fund risk management and risk advisory for Italian and European managers. Studied business economics at Bocconi; the functional Vertis appointment does not imply employment as a Vertis investment partner.

Forty.5 Ventures is a venture capital firm and venture studio operating from Los Angeles, Belgrade and Singapore. It backs pre-seed and seed companies in Southeastern Europe and selectively in the United States and Asia Pacific, focusing on vertical AI, fintech, cybersecurity and consumer technology including gaming, sports and creator infrastructure. Its studio works with existing businesses on go-to-market execution, operations and fundraising readiness. Initial fund investments typically range from USD200,000 to USD1 million.

therapiAI develops an enterprise AI-agent platform for biopharmaceutical companies and contract development and manufacturing organizations. Its purpose-built agents support research, development, quality and pharmaceutical workflows by connecting scientific knowledge with organizational tools and data. The company combines biotechnology, machine learning, pharmaceutical engineering and regulatory expertise, with an emphasis on traceability, governance and practical deployment. Founded in Taiwan in2018, it rebranded as therapiAI and received Cherubic-led seed funding in2024.

WIT Angels Club is a Bucharest-based angel-investor community helping women invest in early-stage technology companies. It provides investment education, shared deal evaluation, mentorship and support for structuring transactions and creating value after investment. Co-founded by Andreea Saia and Ruxandra Muys-Stoian, it promotes diverse founding teams and technology with practical social and economic impact.

Raymond Yuan is a vice president at Pivotal Life Sciences and Nan Fung Group in Hong Kong. He joined the group in 2018 after work in McKinsey's chemicals and agriculture practice. He holds a chemical engineering master's degree from Imperial College London.

Allison Vuong is a senior software engineer at Pivotal Life Sciences, developing data infrastructure for its AI, machine learning and investment teams. Her earlier work included ImmuneBridge consulting, data integration platforms at Genentech and bioinformatics pipelines at Bayer CropScience. She holds a UC Berkeley bioengineering degree.

AJ Velasquez-Mao is a senior associate on Pivotal's San Francisco investment team, which he joined in 2026. He previously invested in early-stage therapeutics at Dolby Family Ventures and covered biotechnology at Jefferies. He holds a joint UC Berkeley/UCSF bioengineering PhD and an undergraduate bioengineering degree from Rice University.

Solo Wu is a vice president at Pivotal Life Sciences and Pivotal bioVenture Partners China. He joined the China operation in 2019 after management consulting in China and Singapore, including L.E.K. Consulting. He holds bachelor's and master's degrees in chemistry from the National University of Singapore.

Ashley Power is an executive assistant in Pivotal's San Francisco operation, which she joined in 2021. Her earlier executive support and operations roles included Bay City Capital and Climate Policy Initiative. She holds an environmental sustainability and social justice degree from San Francisco State University.

Lance Miles is a senior machine learning engineer at Pivotal Life Sciences. He develops production infrastructure and AI tools for biotechnology investment analysis, including applications of large language models. He holds a Master of Information and Data Science degree from UC Berkeley.

Brian Mills is a vice president on Pivotal's San Francisco investment team, which he joined in 2022. He previously covered biotechnology at Jefferies and researched translational biomarkers for neurological and psychiatric diseases as a Stanford postdoctoral scholar. He holds a neuroscience PhD from Oregon Health and Science University.

Ming Luo directs human resources for Pivotal Life Sciences and Pivotal bioVenture Partners China. She joined in 2021 after healthcare and life sciences executive search work at Heidrick & Struggles and other consulting firms. She holds a Washington University in St. Louis MBA and a finance degree from the Central University of Finance and Economics.

Han Li is a data scientist in Pivotal Life Sciences' Shanghai AI and Data Intelligence team. Her experience includes machine learning and statistical analysis in market research and online insurance. She holds a computational biology PhD and statistics master's degree from the University of Southern California, and a biology degree from the University of Science and Technology of China.

Jeni Lee is a partner with Pivotal bioVenture Partners in the US, which she joined in 2019. She invests in therapeutics and life sciences, with an early-stage therapeutics focus, following work at Novo Ventures and Aquilo Capital. She co-founded ViVita Technologies and holds a biomedical engineering PhD from UC Davis and a bioengineering degree from UC Berkeley. She is distinct from the Jennifer Lee records at Basis Set Ventures and Parallel Bio.

Felix Fu is vice president of research on Pivotal's Shanghai AI and Data Intelligence team. He previously worked in biotechnology competitive intelligence and business development, co-founded science communication agency Quisite Science, and worked in McKinsey's healthcare research practice. He holds a PhD in developmental genetics from New York University.

Charlotte Chow is an investment associate in Pivotal's Hong Kong team. She joined Nan Fung Group in 2022 after healthcare investment banking at Fosun Hani Securities. She holds a biomedical science degree from Imperial College London.

Lisa Cai is portfolio manager at Pivotal Life Sciences and a director in the Nan Fung Group CEO office. Her public-equity background includes healthcare investment research at NF Trinity, Agamemnon Capital and SAFE, following private-equity work at Morgan Stanley. She holds an MBA from Wharton and undergraduate degrees from UC Berkeley.

Emerald Bloom-Johnson manages HR and talent for Pivotal Life Sciences. She joined its San Francisco operation in 2019 and supports US human resources and Peter Bisgaard. Her earlier experience spans executive support, real estate investment management, entrepreneurship and events; she studied business marketing at California State University Monterey Bay.

Glenn Batchelder is a venture partner with Pivotal bioVenture Partners in the US. He co-founded and led Civitas Therapeutics and previously served as CEO of BIND Therapeutics and Acceleron Pharma. His biotechnology operating background includes Millennium Pharmaceuticals; he holds a chemical engineering degree from Lehigh University. Glenn Batchelder is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Mischa Travers is US chief operating officer and general counsel at Pivotal Life Sciences, which he joined in 2022. He previously served as CFO and general counsel of Cequence Security and as a partner at Davis Polk & Wardwell. He holds a JD from the University of Chicago and an industrial and systems engineering degree from Virginia Tech.

SeedBlink provides software and financial infrastructure for European startup equity management and financing. Its services include cap tables, employee equity plans, private fundraising rounds, investment syndicates, equity crowdfunding and secondary transactions. It connects technology companies with investors and administers investments made through its platform; platform-funded rounds represent pooled investor capital rather than necessarily SeedBlink’s own balance-sheet investments.

Tigrim is a Swedish family office investing its own evergreen capital in technology, software, sustainable industry and founder-led businesses. It provides long-term ownership and hands-on support without fixed fund cycles or forced exits. Its investments include assistive navigation technology, autonomous freight, space launch, software infrastructure and consumer businesses.

Anna Sun is China chief operating officer at Pivotal Life Sciences and a director in the Nan Fung Group CEO office. Before joining the group she worked in interest-rate structuring at Barclays Capital. She holds bachelor's and master's degrees in finance from Tsinghua University; Anna Xintong Sun is the name used in securities filings.

Tony Ho is senior science partner at Pivotal Life Sciences. A physician and biotechnology R&D executive, he previously led R&D at CRISPR Therapeutics, oncology integration and innovation at AstraZeneca, and neurology and ophthalmology at Merck. He co-founded Neuronyx and holds an electrical engineering degree from UCLA and an MD from Johns Hopkins. He is a different person from General Catalyst engineering partner Tony Ho.

Rob Hopfner is managing director of Pivotal Life Sciences and managing partner of Pivotal bioVenture Partners in the US. He joined in 2017 after investment leadership at Bay City Capital. His background includes pharmacy, a pharmacology doctorate from the University of Saskatchewan, an MBA from Chicago Booth and postdoctoral research at Harvard Medical School. Robert Hopfner is the name used in securities filings.

Vincent Cheung chairs Pivotal Life Sciences and is managing director and chief executive officer of Nan Fung Group. He founded the US Pivotal bioVenture Partners operation in 2017 and its China counterpart in 2018, and studied molecular and cell biology at UC Berkeley.

Adapta Robotics designs and manufactures customizable robots that automate device testing and retail operations. Its MATT systems physically interact with touchscreens, buttons and controls to test hardware and software; ERIS scans store shelves to detect availability and price-label errors; and SIDD monitors inventory with cameras. The company combines robotics, computer vision and AI for customers in electronics, automotive, aerospace, manufacturing and retail. It began as rinf.tech’s robotics department in2015 and became an independent startup in2021.

.lumen (Dotlumen SRL) is a Romanian deep technology company founded in 2020 and based in Cluj-Napoca. It develops Pedestrian Autonomous Driving AI, combining computer vision, onboard environment understanding and directional haptic feedback. Its Glasses for the Blind use six cameras and run navigation locally to identify safe walking paths and guide users through vibrations on the forehead while preserving hearing. The company announced CE certification in May 2025 and is scaling manufacturing with Arrow Electronics, with a Japan pilot supported by Toyota Mobility Foundation in 2026. Its work includes sensory substitution and clinical usability research; it does not claim a neural implant or restoration of biological vision. The same pedestrian AI is being developed for autonomous urban delivery robots. The current site reports over 50 researchers, engineers and designers, but many team members are named only by first name. A €5 million investment closed in January 2025 led by Catalyst Romania, including EIC Fund, Tigrim and €1 million of crowdfunding facilitated by SeedBlink. EIT Urban Mobility announced a further investment in December 2025 with undisclosed amount. EU grants and consortium project budgets are tracked separately from equity financing.

Industrial design lead at .lumen, responsible for the design of assistive glasses and prototypes. The company’s MEDICA 2025 presentation credits his design work with a Red Dot Luminary award.

Founder and CEO of .lumen, which he established to improve independence for visually impaired people, inspired by disability in his family. Formerly Head of Innovation at Continental. Leads development of AI-powered glasses and Pedestrian Autonomous Driving technology.

Hardware lead at .lumen. Her background includes robotics work in Germany, and the company selected her for the EIC Women Leadership Programme in 2023. Works on the electronics and hardware for AI-powered assistive navigation glasses.

Head of Business Development at .lumen as reported in its MEDICA 2025 presentation. The company credits him with helping write its successful EIC business plan. His continued role is not separately confirmed by the current first-name-only team page.

Clinical researcher at .lumen, also described as Testing Manager in the company’s MEDICA 2025 presentation. Works on usability and validation of assistive navigation devices for visually impaired users.

Senior software tester at .lumen as reported in the company’s MEDICA 2025 presentation. Has extensive software testing experience and medical software testing certification under IEC 62304. Current employment is not independently confirmed by the current first-name-only team page.

Clinical researcher at .lumen, contributing to research on usability of AI-based navigation for blind people. Her background includes academic work in public health, including at US universities, as described in the company’s MEDICA 2025 presentation.

Software lead at .lumen, working on software for AI-powered assistive glasses and pedestrian navigation. The company’s MEDICA 2025 presentation identifies him as a Romanian ISEF finalist and Forbes Under 30 honoree.

Navigation lead at .lumen, working on the AI-powered pedestrian navigation stack for assistive glasses. The company’s MEDICA 2025 presentation describes research institute experience and scientific publications.

Gateway Ventures is a Vienna-based startup investment platform connecting private investors, business angels and family offices with European seed and growth-stage technology companies. It selects investment opportunities, coordinates due diligence and legal transactions, and provides portfolio reporting and support. Its focus includes business services, sustainability and health; investors can participate in individual startup deals rather than needing to commit to a conventional venture fund.

Moondust Ventures is a Czech early-stage investment firm backing healthcare and deep technology startups. It invests in digital health, biotechnology, medical devices and technologies such as AI and cybersecurity, and supports founders with strategy, financing and operational advice. Its team combines investment experience with healthcare IT and laboratory expertise through its longstanding partnership with STAPRO’s founders.

Medical Technology Lab (MT-Lab) is a Milan-based investment and operating holding supporting seed-stage healthcare companies. It invests in medical devices, biotechnology, pharmaceuticals and digital health, combining capital with scientific, regulatory, product-development and commercial expertise. Its portfolio includes cognitive biomarker software, antibody therapeutics, retinal-disease treatment and extracellular-vesicle technology.

Catalyst Romania is a technology-focused venture capital firm providing early expansion and growth capital to companies in Romania and neighbouring Central and Eastern European markets. It makes equity and quasi-equity investments, typically EUR1–3 million, and supports portfolio companies with commercial expansion, governance and investor networks. Its portfolio includes AI retail media, robotics, assistive technology and cognitive biomarker software. FundII reached its EUR50 million final close in February2022, before the current three-year research window.

SOMAREALITY develops hardware-agnostic eye-tracking software that measures cognitive load, attention, conscious perception and fatigue in real time. It combines cognitive-science models with machine learning to turn eye movements and pupil dynamics into interpretable digital biomarkers. Its SOMA Aware dashboard, web API, software libraries and Unity SDK serve research, healthcare, aviation, sports and training applications. In June2026 it raised more than EUR3 million in a Series A round led by Catalyst Romania; the exact total was not disclosed.

IntelliProve develops camera-based health-monitoring software that estimates physiological and wellbeing indicators from short optical scans of a person’s face. Its signal-processing and computer-vision technology runs through smartphone cameras without wearables and integrates as a plug-in into digital health, corporate wellbeing and insurance applications. The company also researches autonomic and stress-related biomarkers for preventive health monitoring.

Miles Ahead is a Belgian early-stage venture capital firm and venture studio investing in AI, deep technology and robotics. It combines capital with hands-on support for product development, sales and go-to-market execution. Its portfolio includes camera-based health monitoring, autonomous rail systems, construction robotics and industrial automation. Its second fund is targeting EUR75 million for physical AI and robotics companies in Belgium, the Netherlands, the UK and Ireland; that target is not a completed fund close.

Marc-Olivier Turgeon serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Andrew Miller serves as Board Chair at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines. Alto director appointed in May 2026. Founded Karuna Therapeutics and helped invent its schizophrenia treatment KarXT, now COBENFY, before its acquisition by Bristol Myers Squibb. He chairs Progentos and serves on Montara’s board, and holds chemical engineering degrees from MIT and Illinois.

Dan Janney serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Cassidy Blundell serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Dmitrij Hristodorov serves as Board Director at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Paul Frohna serves as Chief Medical Officer at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Sanjay Magavi serves as Co-Founder and Chief Scientific Officer at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Chris Loose serves as Co-Founder and Chief Executive Officer at Progentos Therapeutics, a biotechnology company developing regenerative neuroscience medicines.

Progentos Therapeutics is a neuroscience biotechnology company developing small-molecule medicines intended to regenerate myelin and address functional loss in multiple sclerosis and other demyelinating diseases. Its approach stimulates endogenous oligodendrocyte progenitor cells to form new oligodendrocytes and remyelinate nerve fibers. The programs are investigational; preclinical findings do not establish clinical benefit in patients. Co-founded by CEO Chris Loose and CSO Sanjay Magavi, the company has operations in Massachusetts and Naarden, the Netherlands, with a current contact address in Cambridge, Massachusetts. Paul Frohna became chief medical officer in October 2025; Andrew Miller chairs its board. Progentos launched publicly in May 2024 with a USD65 million Series A led by Forbion and joined by Alta Partners, Mission BioCapital, Longwood Fund and Dolby Family Ventures. Its current website names three management members and seven board members, with Chris Loose appearing in both groups.

Neuroscience investor and F-Prime venture partner serving on the boards of Engrail Therapeutics and Stellaromics. Joined Stellaromics’ board in February2026; works with neuroscience companies translating academic research toward clinical programs.

Stephen Brannan serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company. Stephen Brannan MD is a published external PureTech collaborator, described as a neuroscience drug-development expert and former chief medical officer of Karuna Therapeutics. His existing Engrail board identity and portrait are preserved. No PureTech employment or personal investment is inferred.

Saira Ramasastry serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Niall O’Donnell serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Neuroscience biotechnology entrepreneur serving on MapLight’s public advisory roster and Engrail’s board. Former Genentech neuroscience leader and co-founder of Alkahest, Circuit Therapeutics and other companies. Trained at Eötvös University, Tulane and UCSF; holds a Stanford psychiatry affiliation.

Heath Lukatch serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Jasper Bos serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Peter Bisgaard is managing director of Pivotal Life Sciences and managing partner of Pivotal bioVenture Partners in the US. He joined Pivotal in 2017 after senior investment roles at Novo Ventures and earlier work at McKinsey. He holds an engineering degree from the Technical University of Denmark and chairs Engrail Therapeutics.

Tiba Aynechi serves as Board Director at Engrail Therapeutics, a precision neuroscience drug-development company.

Rex E. Bosen serves as Senior Vice President, Finance at Engrail Therapeutics, a precision neuroscience drug-development company.

Camilla Gomiero serves as Vice President, Commercial Strategy and Business Development at Engrail Therapeutics, a precision neuroscience drug-development company.

Estibaliz Arce serves as Vice President, Translational Science and Clinical Development at Engrail Therapeutics, a precision neuroscience drug-development company.

Eve Taylor serves as Executive Vice President, Clinical Program Management and Regulatory Affairs at Engrail Therapeutics, a precision neuroscience drug-development company.

Paul Cayer serves as Chief Financial Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

Quentin McCubbin serves as Chief Technical Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

Kimberly Vanover serves as Chief Scientific Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

100IN is a venture investment firm backing technology founders at pre-seed. Founded by former Intuo and Henchman entrepreneurs Gilles Mattelin and Jorn Vanysacker, it aims to write an initial EUR100,000 cheque into 100 startups and support them with experience from building and selling software businesses. The founders fund 60 percent of the vehicle, with other entrepreneurs joining as backers.

RDY Ventures backs Belgian technology startups at the earliest stages, including before revenue. It provides initial EUR100,000 investments, follow-on funding and regular coaching supported by venture partners and an investment committee. Its legal vehicle was established as Birdhouse Ventures in2023 and renamed RDY Ventures in July2025.

Kai Wucherpfennig serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Christophe Weber serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. Christophe P. Weber is a Boston Scientific board director, appointed inFebruary2026. He previously served as Takeda’s chief executive and president after a long career at GlaxoSmithKline. He holds a pharmacy doctorate from Université de Lyon and has accounting and finance training. This is the same healthcare executive published by Longwood Fund as Christophe Weber.

K. Dane Wittrup serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Nobel laureate and MIT biologist studying gene expression and RNA splicing. Chairs Dewpoint's scientific advisory board and serves on Longwood Fund's strategic advisory board. Co-founded Biogen and Alnylam Pharmaceuticals.

Paul Schimmel serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Al Sandrock serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. He is also a director of Transition Bio and President and CEO of Voyager Therapeutics.

Stefan Oelrich serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Fiona Marshall serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Lou Lange serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. Louis “Lou” Lange is a managing member of Asset Management Ventures, LLC, confirmed in its March 2026 SEC filing. The firm’s own team directory brands him as Lou Lange, Partner. NewAmsterdam Pharma’s 2025 annual report published in2026 identifies him as an AMV general partner, physician and founder of CV Therapeutics. His Longwood Fund advisory role is retained.

Sally Kornbluth serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Anne Klibanski serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

William Hait serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Laurie Glimcher serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Stephen Elledge serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Victor Dzau serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Deborah Dunsire serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Jay Bradner serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Lotte Bjerre Knudsen serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Julie Mullen serves as Operations Manager at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Melissa Magner serves as Executive Assistant at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Christina Stephens serves as Executive Assistant at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Kevin Lewis serves as Controller at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Arielle Jackson leads corporate communications and industry engagement at Longwood Fund. She joined in 2017 and co-founded the Longwood Healthcare Leaders conference series. Her education includes a BBA from the University of Massachusetts Amherst. She is distinct from the Stanford-educated First Round marketer of the same name.

Aparaajita Balaji serves as Associate at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Roger Tung serves as Venture Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Sean O’Connor serves as Principal at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Rob Hadfield serves as General Counsel and Operating Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Josh Lubov serves as Chief Financial Officer at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Aleks Radovic-Moreno serves as Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Vikas Goyal serves as Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Rich Aldrich serves as Co-Founder and Partner at Longwood Fund, a biotechnology company builder and life sciences venture investor.

Holmes develops an AI platform that automates quality assurance for web applications, mobile apps and APIs. Its agents learn product workflows and write, run and maintain tests that check user journeys as software changes. Engineering teams use it for regression checks, exploratory testing and accessibility testing within their release workflow.

FREESBEE Ventures invests in applied AI startups whose products perform complete business functions. Its Fund II backs companies from late seed to Series A, primarily in the US, with USD300,000–500,000 co-investments alongside a lead. The firm also offers performance-marketing support through AdQuantum and non-dilutive financing of customer-acquisition cohorts.

NewSchool.vc is an early-stage venture capital firm backing B2B technology that modernizes traditional industries. It invests EUR100,000–500,000 at pre-seed and seed across AI, SaaS, cybersecurity, robotics and compliance, with a European focus. Founder and sole general partner Christophe Morbee combines investment capital with support for sales and go-to-market execution.

A multi-compartment venture capital platform investing in frontier technologies in Italy and Europe. Its NVM Venture Lazio compartment backs pre-seed and seed companies with civilian and defence applications in aerospace, maritime systems, robotics, cybersecurity, AI, energy infrastructure, advanced manufacturing and biotechnology. The legal vehicle is Nevermind (NVM) SICAV-RAIF S.c.A.; Ulixes Capital Lux serves as its general partner. Each compartment has its own thesis and investment team, with shared governance infrastructure.

Neuroscience biotechnology executive serving on Goldman Sachs’ life sciences advisory board.

Biotechnology executive serving on Goldman Sachs’ life sciences advisory board.

Physician-scientist advising Goldman Sachs’ life sciences team, with expertise in endocrinology and obesity research.

Biotechnology executive serving on Goldman Sachs’ life sciences advisory board.

Harvard immunologist and TRexBio scientific founder researching T-cell differentiation, autoimmunity and inflammation. Also serves as a life sciences adviser at Goldman Sachs Alternatives.

Physician-scientist and academic leader who advises Goldman Sachs’ life sciences investment team; research expertise includes balance and inner-ear disorders. Lloyd Minor is published by aMoon as External Adviser. Stanford medical-school dean and physician-scientist whose work includes preventive and personalized medicine. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Goldman Sachs life sciences investor with a background in stem-cell biology and biotechnology venture investing; previously worked at insitro and The Column Group.

Goldman Sachs life sciences investor with biotechnology operations and venture-investing experience; previously worked at Qiming Venture Partners USA.

Life sciences investor at Goldman Sachs, previously a biotechnology investor at Longitude Capital and HealthCor.

Leads Goldman Sachs’ life sciences investment strategy, combining biotechnology finance and corporate transaction experience.

Life Sciences at Goldman Sachs Alternatives is the specialist life sciences investing group within Goldman Sachs Asset Management’s alternatives platform. Established in 2021 and led by Amit Sinha, it invests in private therapeutics companies entering clinical development or in early clinical stages, including neuroscience, precision and genetic medicine, cell therapies, immunotherapy and technologies such as synthetic biology and AI. Its first fund, West Street Life Sciences I, closed in January 2024 with USD650 million in equity commitments. The current strategy page reports more than USD1 billion in aggregate capital raised as of June 2026 and 21 investments as of July 2026; 19 are disclosed and two preclinical companies remain in stealth. These aggregate figures are distinct from the first fund’s size. Verified neuroscience investment Newleos Therapeutics includes the strategy as Series A lead in February 2025. This profile represents the specialist investment team, not a separate corporate entity or all Goldman Sachs businesses.

Michael Liebowitz serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Sanjay Mathew serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Gerard Sanacora serves as Scientific Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Juliane Hellhammer serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company.

Murray Stein serves as Clinical Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company. Murray Stein MD MPH FRCPC is a published external PureTech collaborator and distinguished professor of psychiatry and public health at UC San Diego. His existing Newleos clinical advisory identity and portrait are preserved. This is an external academic affiliation.

Ming Cheah serves as Board Director at Newleos Therapeutics, a clinical-stage neuroscience company.

Raymond Camahort serves as Board Director at Newleos Therapeutics, a clinical-stage neuroscience company. Raymond Camahort, Ph.D., is Partner at Novo Holdings Venture Investments. He has over 15 years of combined investment, business, and research experience, with expertise in biochemistry, genetics, and gene therapy/editing. Prior to joining Novo Ventures, Ray worked in business development at the Harvard University Office of Technology Development where his role was to help facilitate commercialization of technologies developed in the chemistry and stem cell/regenerative biology departments. Ray has served on the Board of Directors of numerous companies, including Ray Therapeutics, Arcellx, Inspirna, iECURE, Riva Therapeutics, and OnCusp Therapeutics. He completed a National Institute of Health post-doctoral training fellowship at Harvard University and was a pre-doctoral fellow at the Stowers Institute for Medical Research in Kansas City, Missouri. He holds a Ph.D. from the University of Kansas in biochemistry and molecular biology and a B.S. in biological sciences from the University of California Santa Barbara.

Christoph Westphal serves as Co-founder and Board Director at Newleos Therapeutics, a clinical-stage neuroscience company.

Biotechnology executive and chairman of Newleos Therapeutics, also serving on Neurogene's board. Previously chief executive officer at 89bio from June 2018 to January 2026, with earlier leadership at Avanir, Medivation and Johnson & Johnson. Holds a Dartmouth MBA and Mumbai commerce and law degrees.

Seth Hopkins serves as Vice President, Clinical Translational Medicine at Newleos Therapeutics, a clinical-stage neuroscience company.

Tiffany Lago serves as Vice President, Clinical Development at Newleos Therapeutics, a clinical-stage neuroscience company.

Marcelo Gutiérrez serves as Vice President, Clinical Pharmacology at Newleos Therapeutics, a clinical-stage neuroscience company.

Hector Guzman serves as Vice President, CMC and Technical Operations at Newleos Therapeutics, a clinical-stage neuroscience company.

Jennifer Gervasi serves as Vice President, Program Management at Newleos Therapeutics, a clinical-stage neuroscience company.

Kyle Audi serves as Vice President, Finance at Newleos Therapeutics, a clinical-stage neuroscience company.

Brian Shea serves as Vice President, Head of Legal at Newleos Therapeutics, a clinical-stage neuroscience company.

Chris Jepsen serves as Vice President, Quality at Newleos Therapeutics, a clinical-stage neuroscience company.

Adam Simmons serves as Vice President, Clinical Operations & Development at Newleos Therapeutics, a clinical-stage neuroscience company.

John McCabe serves as Chief Financial Officer at Newleos Therapeutics, a clinical-stage neuroscience company.

Lea Hachigian serves as Senior Vice President, Corporate Strategy and Operations at Newleos Therapeutics, a clinical-stage neuroscience company.

Sondra Smyrnios serves as Senior Vice President, Clinical and Technical Operations at Newleos Therapeutics, a clinical-stage neuroscience company.

Federico Bolognani serves as Co-founder, Chief Medical Officer at Newleos Therapeutics, a clinical-stage neuroscience company.

Timothy Noyes serves as Chief Executive Officer at Newleos Therapeutics, a clinical-stage neuroscience company.

Kinestica develops sensor-based medical devices and software for neurological rehabilitation. Its Bimeo system supports upper-limb therapy and its Equio system trains balance and postural control, combining interactive exercises with objective movement measurements and patient progress reports for therapists.

NOW technologies develops electronic controls that help people with paralysis and other mobility impairments operate powered wheelchairs and computers. Its Switch-It Vigo head-drive kit translates head movements into wireless wheelchair and mouse commands; its Actuator Direct Controller adjusts wheelchair seating. The Budapest company joined Sunrise Medical through an acquisition announced in September 2022.

Synetiq developed advertising research that combines neuroscience, biometric measurements and machine learning to assess how audiences respond emotionally to video advertisements. Its analysis of EEG, eye tracking, heart rate and skin conductance helped brands and media producers evaluate creative material. Day One lists it as an exited investment; its former company website is currently expired.

Arkin Bio Capital is the clinical-stage biotechnology investment fund within Arkin Capital’s Arkin Bio platform. Established in 2021, it finances clinical proof of concept and later-stage development, distinct from the group’s early-stage Arkin Bio Ventures funds. Pini Orbach is managing partner overseeing both sets of funds. Verified investments include Reunion Neuroscience’s Series A and HI-Bio’s January 2024 Series B. A 2026 SEC filing separately identifies Arkin Bio Capital L.P., its general partner and Arkin Bio Ventures II L.P., confirming that these are distinct vehicles. The reviewed primary manager pages do not disclose this fund’s closed capital; Arkin Capital’s aggregate AUM is not assigned as fund size.

Arkin assistant controller, supporting financial statements and tax-compliance reporting.

Arkin director of finance, responsible for financial reporting and investor communications.

Arkin tax director, responsible for tax planning, compliance and investment-related taxation.

Managing partner responsible for Arkin’s real-estate investment platform and international property portfolio.

Arkin operations and maintenance manager, providing technical and practical support to the organization.

Managing partner of A², the successor brand to Arkin Digital Health, overseeing digital-health investment and portfolio support.

Arkin executive assistant and office manager, coordinating executive schedules, travel, meetings and corporate events.

Arkin bookkeeper and payroll accountant, supporting financial records, employee payments and tax reporting.

Boston-based partner at Arkin Bio, joining in 2026 after biotechnology investment roles at Leaps by Bayer and RA Capital.

Principal in Arkin’s real-estate business, responsible for investment analysis, acquisitions and portfolio management.

Arkin Bio investment analyst with doctoral training in neuroscience, conducting scientific and financial diligence; joined in 2024.

Arkin bookkeeper handling supplier accounts, reconciliation and administration of charitable donations.

Principal within Arkin Equity, working on hedge-fund strategy and private-equity transactions.

Arkin legal counsel, advising on corporate transactions, financing and commercial agreements; joined in 2018.

Arkin Equity investment professional focused on private and direct equity transactions, including company analysis and underwriting.

Arkin bookkeeper supporting cash management, trading records and financial reporting; joined in 2010.

Arkin investment analyst with pharmaceutical-sciences training, focused on biotechnology diligence; joined in 2025 after working at Sphera.

Principal at Arkin Bio Ventures and member of the third early-stage fund’s management team. Trained in neural computation and previously invested at aMoon.

Principal at Arkin Bio Ventures and member of the third early-stage fund’s management team. Biotechnology scientist with corporate-development and licensing experience.

Managing partner leading Arkin Equity’s hedge-fund, private-equity and company-building activities.

CFO of Arkin Capital, overseeing finance, taxation, fund operations and corporate systems; joined in 2015.

Arkin Capital director responsible for international securities and external fund-manager allocations; also participates in technology investment decisions.

Founder and chairman of Arkin Capital. Built pharmaceutical company Agis before its sale to Perrigo, then established the investment group in 2009.

CEO of Arkin Capital, responsible for developing the group’s investment platforms and institutional relationships; joined in 2014.

Develops AI software that turns radar signals into perception data for autonomous vehicles and robots. Its products estimate motion and free space, detect and classify objects, and combine radar with camera information. The platform supports different radar hardware for automotive, industrial robotics and other applications where reliable perception is needed in difficult conditions.

Develops adaptive control software for industrial robots handling variable assembly and disassembly tasks. Its system combines perception, planning and force-aware control so robotic cells can work with changing parts and environments. Initial applications include electric-vehicle battery disassembly, drone assembly and automotive cable harnessing; the company is developing industrial pilots.

Develops high-altitude balloon platforms for Earth observation. Its systems carry imaging and sensor payloads in the stratosphere, using atmospheric modeling and navigation software to collect detailed geospatial data over large areas. The company is developing monitoring applications for infrastructure, agriculture, environmental change, disaster response and security.